MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
about
Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomasCirculating glioma biomarkersO(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problemsDNA methylation biomarkers: cancer and beyondOligodendroglioma: pathology, molecular mechanisms and markersCIViC databaseNETRIN-4 protects glioblastoma cells FROM temozolomide induced senescenceThe global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for gliomaRecursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumorsInternational retrospective study of over 1000 adults with anaplastic oligodendroglial tumorsAssessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.Molecular Testing of Brain Tumor.First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.Recurrent high-grade glioma: a diagnostic and therapeutic challenge.Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapiesMedical therapy of gliomas.Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Altered expression of MGMT in high-grade gliomas results from the combined effect of epigenetic and genetic aberrations.Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markersThe future of high-grade glioma: Where we are and where are we going.Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments.Molecular profile of oligodendrogliomas in young patientsClinicopathological significance and potential drug target of O6-methylguanine-DNA methyltransferase in colorectal cancer: a meta-analysis.MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers.MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCRMalignant brainstem gliomas in adults: clinicopathological characteristics and prognostic factors.O6-Methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions.Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-statusThe prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.Lower MGMT expression predicts better prognosis in proneural-like glioblastomaAdult brainstem gliomas: Correlation of clinical and molecular features.Personalized treatment strategies in glioblastoma: MGMT promoter methylation status.Recent advances and future of immunotherapy for glioblastoma.Correlation of histomorphologic prognostic markers and proliferative index with loss of heterozygosity 1p/19q and MGMT status in diffusely infiltrating gliomas.Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas.Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patientsPrognostic markers in gliomas.
P2860
Q24194645-422B6337-F079-4639-B45C-937AD4412DD2Q26830329-B3F95EC1-988E-4089-B786-87F30D675953Q26853112-68278543-D08B-4886-BDA1-6AB0CCF8563DQ26996421-12543CAA-67BA-44A4-A75C-0D929BBEF957Q27002448-4223977B-7ACB-425A-9B01-FB27078E6B14Q27612411-E810DBA5-41D1-43F9-9326-6C309FB6305CQ28535039-C1F08F1F-4F65-4B50-901C-BA7AD0382500Q28741768-FFC325CD-EFF5-4095-B53E-78CF97D243B3Q30370204-92B93B69-D749-4BBA-8FB0-86EB461113E4Q30426724-A1DFCBC6-C246-4072-9D83-FC1BB1E768FEQ30836702-66DC9E8D-303C-482A-9E65-31FBCE097E31Q33729693-8BD59787-36DF-4E61-AB27-62EB8CCB51B4Q33777877-6F938D02-0030-464D-B9ED-3F635AFAB073Q33864058-3C6CA2FE-3435-437B-AC4A-B6D7F1CA3264Q33925544-075FB3F8-D6C6-4A88-8313-852FB1FA41D3Q34218761-C333ADDC-A02C-4217-838A-680AD1A28E5CQ34478948-C38A19D2-991E-46B8-8747-017916953805Q34620657-94EE34D0-1772-45E3-AAB3-E24F1DB9C384Q34625644-861FC986-555A-4032-98BE-A46D2B36A007Q34815207-A86A5D22-915C-48C3-92E8-F2731D111B09Q35114090-70AF07BD-FA36-4FE2-BFAA-6FC768D11B43Q35161909-1B17C880-2DF8-4073-8C86-C46EC48D1925Q35225293-CDD11F20-7EF2-49F8-BAC8-36E7A121F551Q35567859-29068C43-4F77-4392-B200-3122359E3405Q35755035-920FF035-8431-458C-AA91-9A97594515C3Q35850389-F9AFE50F-7D0C-4653-9572-4AC2805FBEBDQ35877530-5F4F1AAF-2475-425C-A231-B18B3A8BD096Q36096925-424F194C-5731-4673-B391-589A814765DAQ36112002-26B7A605-0EC1-4FE3-A2F6-1431E2CBA188Q36240860-C07A7F20-DB83-474B-8DFE-2F8B4BCFAA1BQ36299167-A28DFF1A-DC02-42CD-8C8B-1CA5989E3067Q36344709-6EA15AAA-8F00-40B3-95AE-5E813BB6A75FQ36492682-B13DFDA4-ABB8-462C-80DB-8616830E6148Q36663080-E988DFF6-1895-4481-BB1C-FA8F3C20487DQ37221207-B53192D2-7301-4072-BE19-D0B864999BD7Q37239071-F64555EE-D307-4D90-B914-4F218CC2C421Q37390680-3C32A4A1-8A21-47CD-BF17-E62971B2ECB7Q37409721-84C9438B-7AF3-4B5A-8320-C6BC3B9E7259Q37418411-46C4266C-89CB-492E-AE3C-D4025B0DFF76Q37750781-4090DBD0-2640-4F34-88DE-B2653039E7A2
P2860
MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
MGMT promoter methylation is p ...... Brain Tumor Group Study 26951.
@ast
MGMT promoter methylation is p ...... Brain Tumor Group Study 26951.
@en
MGMT promoter methylation is p ...... Brain Tumor Group Study 26951.
@nl
type
label
MGMT promoter methylation is p ...... Brain Tumor Group Study 26951.
@ast
MGMT promoter methylation is p ...... Brain Tumor Group Study 26951.
@en
MGMT promoter methylation is p ...... Brain Tumor Group Study 26951.
@nl
altLabel
MGMT Promoter Methylation Is P ...... Brain Tumor Group Study 26951
@en
prefLabel
MGMT promoter methylation is p ...... Brain Tumor Group Study 26951.
@ast
MGMT promoter methylation is p ...... Brain Tumor Group Study 26951.
@en
MGMT promoter methylation is p ...... Brain Tumor Group Study 26951.
@nl
P2093
P2860
P921
P356
P1476
MGMT promoter methylation is p ...... Brain Tumor Group Study 26951.
@en
P2093
Ahmed Ibdaih
Alba A Brandes
Cathleen R van der Lee-Haarloo
Denis Lacombe
Hendrikus J Dubbink
Johan M Kros
Judith W M Jeuken
Marc Frenay
Marc Sanson
Martin J B Taphoorn
P2860
P304
P356
10.1200/JCO.2009.24.1034
P407
P577
2009-12-10T00:00:00Z